JP2025536506A5 - - Google Patents

Info

Publication number
JP2025536506A5
JP2025536506A5 JP2025514713A JP2025514713A JP2025536506A5 JP 2025536506 A5 JP2025536506 A5 JP 2025536506A5 JP 2025514713 A JP2025514713 A JP 2025514713A JP 2025514713 A JP2025514713 A JP 2025514713A JP 2025536506 A5 JP2025536506 A5 JP 2025536506A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
particles
recombinant
injection
scaav particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025514713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025536506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/074351 external-priority patent/WO2024059823A1/en
Publication of JP2025536506A publication Critical patent/JP2025536506A/ja
Publication of JP2025536506A5 publication Critical patent/JP2025536506A5/ja
Pending legal-status Critical Current

Links

JP2025514713A 2022-09-15 2023-09-15 優性阻害型ＲｈｏＡを運ぶ自己相補型ＡＡＶベクターおよび眼疾患を治療するための使用方法 Pending JP2025536506A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263407150P 2022-09-15 2022-09-15
US63/407,150 2022-09-15
US202263414996P 2022-10-11 2022-10-11
US63/414,996 2022-10-11
US202263426725P 2022-11-19 2022-11-19
US63/426,725 2022-11-19
PCT/US2023/074351 WO2024059823A1 (en) 2022-09-15 2023-09-15 Self-complementary AAV vectors carrying dominant negative RhoA and methods of use to treat ocular diseases

Publications (2)

Publication Number Publication Date
JP2025536506A JP2025536506A (ja) 2025-11-07
JP2025536506A5 true JP2025536506A5 (OSRAM) 2026-05-15

Family

ID=90275835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025514713A Pending JP2025536506A (ja) 2022-09-15 2023-09-15 優性阻害型ＲｈｏＡを運ぶ自己相補型ＡＡＶベクターおよび眼疾患を治療するための使用方法

Country Status (7)

Country Link
US (1) US20240100193A1 (OSRAM)
EP (1) EP4587055A1 (OSRAM)
JP (1) JP2025536506A (OSRAM)
KR (1) KR20250067171A (OSRAM)
CN (1) CN120302995A (OSRAM)
CA (1) CA3265312A1 (OSRAM)
WO (1) WO2024059823A1 (OSRAM)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094326A1 (en) * 2017-11-08 2019-05-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using rhoa dominant negative forms

Similar Documents

Publication Publication Date Title
US11583595B2 (en) Modified mGluR6 promoter and methods of use
JP2023545722A5 (OSRAM)
JP2022529775A5 (OSRAM)
WO2017070491A1 (en) Ophthalmic formulations
US20230265455A1 (en) Improved aav-mediated x-linked retinoschisis therapies
US20210188927A1 (en) Compositions and methods for treating age-related macular degeneration
US20260001917A1 (en) Modified adeno-associated virus capsid proteins and methods thereof
JP2023139317A (ja) 医薬の製造におけるＣＹＰ４Ｖ２およびＲｄＣＶＦの使用
JP2021510301A5 (OSRAM)
US12371474B2 (en) Recombinant adeno-associated viral vectors for treating Bietti Crystalline Dystrophy
CN114144518A (zh) 用于基因疗法的双亮氨酸拉链激酶抑制剂
JP2023547832A5 (OSRAM)
JP2022533645A (ja) グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善
JP2022533983A5 (OSRAM)
CA3103203A1 (en) Materials and methods for modulating intraocular and intracranial pressure
JP7624727B2 (ja) 合理的設計により増強された新規なａａｖウイルスによる網膜における高効率の形質導入および側方への広がり
US20240141015A1 (en) Vector-mediated immune tolerance in the eye
EP4048319A1 (en) Methods for treating patients having cfh mutations with cfh-encoding vectors
JP2023548145A5 (OSRAM)
CN115997012B (zh) Rpe65相关眼睛疾病和障碍的治疗
RU2025132907A (ru) Нуклеиновая кислота, кодирующая белок, специфичный к vegf, полинуклеотидная кассета экспрессии и рекомбинантный аденоассоциированный вирус
WO2022204077A1 (en) Arsb vectors for treatment of mps vi-associated blindness and other ocular manifestations
CA3169548A1 (en) Aav-naglu vectors for treatment of mucopolysaccharidosis iiib